Seeking Alpha

Incyte and MedImmune collaborate on cancer immunotherapies

  • AstraZeneca (AZN -0.3%) biologics R&D unit MedImmune and Incyte (INSY -6%) collaborate on a Phase 1/2 clinical trial to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor MEDI4736 in combination with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
  • MEDI4736 blocks the signals that help tumors avoid detection by the immune system while INCB24360 enhances immune cells' ability to fight the tumor.
  • The two firms collaborate on a non-exclusive basis. They expect the Phase 1 trial to establish a recommended dose regimen and Phase 2 to assess the safety and efficacy of the combination. Further development of the combo is contingent on the results of the trials.
Comments (1)
  • 413105
    , contributor
    Comments (3) | Send Message
     
    The combination immunotherapy of Anti-PD-L1 & IDO inhibitor should show a synergistic efficacy in combating cancer. As, a stage IV cancer survivor, I been researching combination for almost 10 years. The cure for cancer will be from combinatorial immunotherapy.

     

    http://bit.ly/1qCS4V7

     

    Best regards,

     

    jimmy B
    14 May, 10:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector